NCT02037347View on ClinicalTrials.gov

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Toxic Epidermal NecrolysisStevens-Johnson Syndrome

Interventions

DRUG

Palifermin

Trial Locations (2)

06610

Bridgeport Hospital, Bridgeport

06510

Yale-New Haven Hospital, New Haven

Sponsors

Collaborators (1)

Swedish Orphan Biovitrum

All Listed Sponsors

collaborator

Swedish Orphan Biovitrum

INDUSTRY

lead

Brett King

OTHER